GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

NCT04731272 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Cystic Fibrosis
Pancreatic Insufficiency
Abnormal Glucose Tolerance
Diabetes

Interventions

DRUG: Dulaglutide 0.75Mg/0.5Ml Inj Pen

Sponsor

University of Pennsylvania

Collaborators

[object Object]
[object Object]